Shelton Capital Management’s AbbVie ABBV Stock Holding History

Shelton Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,900	Closed	-$308K	–	714
2022 Q1	$308K	Buy	+1,900	New	+$276K	0.01%	533

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Shelton Capital Management's ABBV Position: Q2 2026 in Review

Shelton Capital Management reduced its AbbVie (ABBV) stake by 14% in Q2 2026, selling an estimated $1.52M and leaving 42,182 shares worth $10.6M. The position accounts for 0.2% of the portfolio, ranked #102.

Shelton Capital Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $21.5M in Q2 2024. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Shelton Capital Management held 42,182 shares of AbbVie worth $10.6M as of Q2 2026.
Shelton Capital Management sold 7,062 AbbVie shares in Q2 2026, an estimated $1.52M.
AbbVie made up 0.2% of Shelton Capital Management's portfolio in Q2 2026, its #102 holding.
Shelton Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Shelton Capital Management's AbbVie position peaked at $21.5M in Q2 2024.
4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.